Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: NOVARTIS
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
An open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension
To evaluate the long-term safety and tolerability of QTI571 in patients with severe pulmonary arterial hypertension.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
Study assessing the safety and tolerability of 0.5 mg ranibizumab in mono/bilateral wet AMD patients in eyes with BCVA below 2/10 and/or second affected eye. Studio per valutare la sicurezza e la tollerabilità di ranibizumab 0.5 mg in pazienti affetti da wAMD mono/bilaterale in occhi con BCVA inferiore a 2/10 e/o patologia del secondo occhio
The primary objective of the present study is to evaluate the annual incidence of both ocular and systemic drug-related adverse events following ranibizumab treatment in patients diagnosed with wAMD a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS
Update Il y a 4 ans
Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients
This will be a single dose Proof-of-Concept study in mild-to-moderate COPD patients. The study will investigate the safety and tolerability of QAX028 as well as the bronchodilatory effects...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS
Update Il y a 4 ans
Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients
Was to evaluate the safety, tolerability and efficacy of multiple doses of canakinumab (ACZ885) vs. placebo when administered via intravenous infusion (IV), on pulmonary function in patien...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two doses of indacaterol (150 and 300 μg o.d.) in patients with chronic obstructive pulmonary disease
To assess the safety of two indacaterol doses (150 and 300 μg o.d. via SDDPI) in patients with moderate to severe COPD as compared to placebo after 52 weeks of treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS
Update Il y a 4 ans
Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis
This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of jo...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS
Update Il y a 4 ans
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.
Country
Germany
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 and IV bortezomib in adult patients with multiple myeloma
To determine the MTD of LBH589 and bortezomib when administered in combination
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after failure of sorafenib treatment The EVOLVE-1 Study
The primary objective of this study is to compare overall survival between the combination treatment of everolimus plus BSC to placebo plus BSC in patients with advanced HCC whose disease progressed ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study (IMPRES)
To evaluate the efficacy of QTI571 compared to placebo as measured by the change in 6- minute walk distance (6MWD) from baseline to 24-weeks
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
4
5
6
7
8
9
10
Next